Clinical Report: Oral BTK Inhibitor Shows Disability Benefit in PPMS Trial

Overview

Roche's fenebrutinib demonstrated non-inferiority to OCREVUS in reducing disability progression in primary progressive multiple sclerosis (PPMS) patients. The trial results indicated a 12% numerical reduction in disability progression risk and significant benefits in upper limb function.

Background

Primary progressive multiple sclerosis (PPMS) is characterized by gradual worsening of neurological function without relapses, and treatment options are limited. OCREVUS is currently the only approved disease-modifying therapy for PPMS, highlighting the need for alternative therapies. Fenebrutinib, an oral BTK inhibitor, offers a promising new approach to managing this challenging condition.

Data Highlights

Key Findings

• Fenebrutinib met the primary endpoint of non-inferiority to OCREVUS in PPMS.
• Numerical 12% reduction in the risk of disability progression compared to OCREVUS.
• Significant improvement in upper limb function, reducing worsening by 26%.
• Consistent treatment effects observed across patient subgroups.
• Safety profile comparable to OCREVUS, with common adverse events including infections and liver enzyme elevations.

Clinical Implications

The findings suggest that fenebrutinib may provide a new oral treatment option for patients with PPMS, potentially improving upper limb function and overall disability outcomes. Clinicians should consider the implications of these results when discussing treatment options with patients.

Conclusion

Fenebrutinib shows promise as a non-inferior alternative to OCREVUS in managing disability progression in PPMS, with specific benefits in upper limb function. Further regulatory review and clinical application are anticipated.

References

1. Roche, ACTRIMS Forum, 2026 -- Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis
2. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis - PubMed, 2017
3. Practice Guideline Recommendations: Disease-modifying Therapies for Adults with Multiple Sclerosis
4. Acta Neuropathologica — Inhibition of BTK Reduces CNS Inflammation Driven by Microglia and Enhances Myelin Regeneration
5. the pathologist — Oral Bacterium Worsens Multiple Sclerosis
6. Acta Neuropathologica — Modulation of B-cell Metabolism by BTK Inhibition Reduces B-cell–T-cell Interactions: Potential Impact on Multiple Sclerosis Treatment
7. baptist health south florida — Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis
8. Inhibition of BTK Reduces CNS Inflammation Driven by Microglia and Enhances Myelin Regeneration
9. Oral Bacterium Worsens Multiple Sclerosis
10. Modulation of B-cell Metabolism by BTK Inhibition Reduces B-cell–T-cell Interactions: Potential Impact on Multiple Sclerosis Treatment
11. Practice Guideline Recommendations: Disease-modifying Therapies for Adults with Multiple Sclerosis
12. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis - PubMed
13. Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study